Somatostatin receptors in non-neuroendocrine malignancies: the potential role of somatostatin analogs in solid tumors (Q37898112)

25 August 2017

1 reference

title

Somatostatin receptors in non-neuroendocrine malignancies: the potential role of somatostatin analogs in solid tumors (English)

1 reference

25 August 2017

1 reference

ChEBI release 2020-05-28

Jens Hasskarl

1

1 reference

25 August 2017

Martina Kaufmann

series ordinal

2

1 reference

25 August 2017

Herbert A Schmid

series ordinal

3

1 reference

25 August 2017

language of work or name

English

0 references

publication date

1 July 2011

1 reference

25 August 2017

1 reference

25 August 2017

7

1 reference

25 August 2017

7

1 reference

25 August 2017

895-913

1 reference

The pathophysiological consequences of somatostatin receptor internalization and resistance

25 August 2017

1 reference

Somatostatin and its receptor family

21 January 2018

1 reference

Opportunities in somatostatin research: biological, chemical and therapeutic aspects

21 January 2018

1 reference

Antitumor effects of somatostatin

21 January 2018

1 reference

Central and peripheral actions of somatostatin on the growth hormone-IGF-I axis

21 January 2018

1 reference

Rationale for the use of somatostatin analogs as antitumor agents

21 January 2018

1 reference

Inhibition of growth and metastatic progression of pancreatic carcinoma in hamster after somatostatin receptor subtype 2 (sst2) gene expression and administration of cytotoxic somatostatin analog AN-238.

21 January 2018

1 reference

Induction of wild-type p53, Bax, and acidic endonuclease during somatostatin-signaled apoptosis in MCF-7 human breast cancer cells

21 January 2018

1 reference

Activation of human somatostatin receptor 2 promotes apoptosis through a mechanism that is independent from induction of p53.

21 January 2018

1 reference

Somatostatin receptor (SSTR) subtype-selective analogues differentially suppress in vitro growth hormone and prolactin in human pituitary adenomas. Novel potential therapy for functional pituitary tumors

21 January 2018

1 reference

Somatostatin inhibits tumor angiogenesis and growth via somatostatin receptor-3-mediated regulation of endothelial nitric oxide synthase and mitogen-activated protein kinase activities.

21 January 2018

1 reference

Somatostatin receptor subtype-dependent regulation of nitric oxide release: involvement of different intracellular pathways.

21 January 2018

1 reference

Induction of a negative autocrine loop by expression of sst2 somatostatin receptor in NIH 3T3 cells

21 January 2018

1 reference

Somatostatin receptor subtype 2 sensitizes human pancreatic cancer cells to death ligand-induced apoptosis

21 January 2018

1 reference

From somatostatin to octreotide LAR: evolution of a somatostatin analogue

21 January 2018

1 reference

Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group

21 January 2018

1 reference

Pasireotide (SOM230): development, mechanism of action and potential applications

21 January 2018

1 reference

Functional activity of the multiligand analog SOM230 at human recombinant somatostatin receptor subtypes supports its usefulness in neuroendocrine tumors

21 January 2018

1 reference

Somatostatin receptor 1 (SSTR1)-mediated inhibition of cell proliferation correlates with the activation of the MAP kinase cascade: role of the phosphotyrosine phosphatase SHP-2.

21 January 2018

1 reference

Somatostatin, acting at receptor subtype 1, inhibits Rho activity, the assembly of actin stress fibers, and cell migration.

21 January 2018

1 reference

Anti-migratory and anti-invasive effect of somatostatin in human neuroblastoma cells: involvement of Rac and MAP kinase activity

21 January 2018

1 reference

Deregulated human glioma cell motility: inhibitory effect of somatostatin.

21 January 2018

1 reference

Inhibition of endothelial proliferation by the somatostatin analogue SOM230.

21 January 2018

1 reference

Octreotide, a somatostatin analogue, mediates its antiproliferative action in pituitary tumor cells by altering phosphatidylinositol 3-kinase signaling and inducing Zac1 expression

21 January 2018

1 reference

Somatostatin analogues stimulate p27 expression and inhibit the MAP kinase pathway in pituitary tumours.

21 January 2018

1 reference

The IGF‐1 receptor in cancer biology

21 January 2018

1 reference

SOM230: a new somatostatin peptidomimetic with potent inhibitory effects on the growth hormone/insulin-like growth factor-I axis in rats, primates, and dogs

21 January 2018

1 reference

Pasireotide (SOM230) demonstrates efficacy and safety in patients with acromegaly: a randomized, multicenter, phase II trial

21 January 2018

1 reference

Clinical perspective: acromegaly and cancer: a problem

21 January 2018

1 reference

Global cancer statistics, 2002

21 January 2018

1 reference

Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study

21 January 2018

1 reference

Clinical implications of neuroendocrine differentiation in prostate cancer

21 January 2018

1 reference

New perspective in the management of neuroendocrine differentiation in prostate adenocarcinoma.

21 January 2018

1 reference

Neuroendocrine differentiation in prostate cancer: implications for new treatment modalities

21 January 2018

1 reference

Localization and mRNA expression of somatostatin receptor subtypes in human prostatic tissue and prostate cancer cell lines

21 January 2018

1 reference

Expression of somatostatin receptor subtypes 2 and 4 in human benign prostatic hyperplasia and prostatic cancer.

21 January 2018

1 reference

Identification of prognostic biomarkers for prostate cancer

21 January 2018

1 reference

Regulation of growth factors in hormone- and drug-resistant prostate cancer cells by synergistic combination of docetaxel and octreotide

21 January 2018

1 reference

The combination of docetaxel and the somatostatin analogue lanreotide on androgen-independent docetaxel-resistant prostate cancer: experimental data.

21 January 2018

1 reference

Regulation of prostate cancer cell proliferation by somatostatin receptor activation.

21 January 2018

1 reference

Insulin-like growth factor 1 in relation to prostate cancer and benign prostatic hyperplasia

21 January 2018

1 reference

ABC of breast diseases. Breast cancer-epidemiology, risk factors, and genetics

21 January 2018

1 reference

Somatostatin receptors in primary human breast cancer: quantitative analysis of mRNA for subtypes 1--5 and correlation with receptor protein expression and tumor pathology

21 January 2018

1 reference

Insulin-like growth factor (IGF)-I, IGF binding protein-3, and cancer risk: systematic review and meta-regression analysis

21 January 2018

1 reference

IGF-I and breast cancer: a meta-analysis

21 January 2018

1 reference

Insulin-like growth factor (IGF)-I and IGF-binding protein 3 and the risk of premenopausal breast cancer: a meta-analysis of literature.

21 January 2018

1 reference

Growth hormone and insulin-like growth factor-I in the transition from normal mammary development to preneoplastic mammary lesions

21 January 2018

1 reference

The novel somatostatin analog SOM230 is a potent inhibitor of hormone release by growth hormone- and prolactin-secreting pituitary adenomas in vitro

21 January 2018

1 reference

Growth of human breast cancer cell lines is inhibited by the somatostatin analog BIM23014.

21 January 2018

1 reference

SOM230 inhibits insulin-like growth factor-I action in mammary gland development by pituitary independent mechanism: mediated through somatostatin subtype receptor 3?

21 January 2018

1 reference

Pasireotide, an IGF-I action inhibitor, prevents growth hormone and estradiol-induced mammary hyperplasia.

21 January 2018

1 reference

A randomized, double-blind, placebo-controlled, phase 3 trial comparing SMS 201-995 pa LAR plus tamoxifen versus tamoxifen plus placebo in women with locally recurrent or metastatic breast cancer

21 January 2018

1 reference

A randomized, multicenter prospective trial assessing long-acting release octreotide pamoate plus tamoxifen as a first line therapy for advanced breast carcinoma

21 January 2018

1 reference

Effects of tamoxifen and octreotide LAR on the IGF-system compared with tamoxifen monotherapy

21 January 2018

1 reference

Cancer survival and incidence from the Surveillance, Epidemiology, and End Results (SEER) program

21 January 2018

1 reference

Primary ovarian cancer chemotherapy: current standards of care

21 January 2018

1 reference

Human ovarian cancers express somatostatin receptors

21 January 2018

1 reference

Insulin-like growth factor binding protein-2 stimulates proliferation and activates multiple cascades of the mitogen-activated protein kinase pathways in NIH-OVCAR3 human epithelial ovarian cancer cells

21 January 2018

1 reference

Insulin-like growth factor binding protein 2 promotes ovarian cancer cell invasion

21 January 2018

1 reference

Inhibition of human epithelial ovarian cancer cell growth in vitro by somatostatin analog RC-160.

21 January 2018

1 reference

Antagonists of growth hormone-releasing hormone and somatostatin analog RC-160 inhibit the growth of the OV-1063 human epithelial ovarian cancer cell line xenografted into nude mice

21 January 2018

1 reference

Octreotide: an active agent in epithelial ovarian carcinoma?

21 January 2018

1 reference

Long-acting octreotide for the treatment and symptomatic relief of bowel obstruction in advanced ovarian cancer

21 January 2018

1 reference

Palliation of malignant intestinal obstruction using octreotide

21 January 2018

1 reference

Relationship between somatostatin receptor subtype expression and clinicopathology, Ki-67, Bcl-2 and p53 in colorectal cancer

21 January 2018

1 reference

Somatostatin inhibits colon cancer cell growth through cyclooxygenase-2 downregulation.

21 January 2018

1 reference

A randomised trial of octreotide vs best supportive care only in advanced gastrointestinal cancer patients refractory to chemotherapy

21 January 2018

1 reference

Sorafenib in advanced hepatocellular carcinoma

21 January 2018

1 reference

Differential expression of somatostatin receptor subtypes in hepatocellular carcinomas

21 January 2018

1 reference

Cortistatin production by HepG2 human hepatocellular carcinoma cell line and distribution of somatostatin receptors

21 January 2018

1 reference

Expression of somatostatin receptors in normal and cirrhotic human liver and in hepatocellular carcinoma

21 January 2018

1 reference

Mechanisms and influence of octreotide-induced regulation of somatostatin receptor 2 on hepatocellular carcinoma

21 January 2018

1 reference

SOM230 combined with celecoxib prolongs the survival in nude mice with HepG-2 xenografts

21 January 2018

1 reference

Treatment of advanced hepatocellular carcinoma with long-acting octreotide: a phase III multicentre, randomised, double blind placebo-controlled study

21 January 2018

1 reference

Sorafenib plus octreotide is an effective and safe treatment in advanced hepatocellular carcinoma: multicenter phase II So.LAR. study

21 January 2018

1 reference

Oxidative stress and ERK1/2 phosphorylation as predictors of outcome in hepatocellular carcinoma patients treated with sorafenib plus octreotide LAR.

21 January 2018

1 reference

Preclinical evaluation of therapeutic effects of targeted cytotoxic analogs of somatostatin and bombesin on human gastric carcinomas.

21 January 2018

1 reference

Enhanced inhibitive effects of combination of rofecoxib and octreotide on the growth of human gastric cancer

21 January 2018

1 reference

Preoperative growth inhibition of human gastric adenocarcinoma treated with a combination of celecoxib and octreotide

21 January 2018

1 reference

Human pancreatic cancer cell lines do not express receptors for somatostatin

21 January 2018

1 reference

Characterization of somatostatin receptor expression in human pancreatic cancer using real-time RT-PCR.

21 January 2018

1 reference

Thrombospondin-1 is a critical effector of oncosuppressive activity of sst2 somatostatin receptor on pancreatic cancer

21 January 2018

1 reference

Immunohistochemical detection of somatostatin receptor types 1-5 in medullary carcinoma of the thyroid

21 January 2018

1 reference

Selective activation of somatostatin receptor subtypes differentially modulates secretion and viability in human medullary thyroid carcinoma primary cultures: potential clinical perspectives.

21 January 2018

1 reference

Evidence for Somatostatin receptor 2 in thyroid tissue.

21 January 2018

1 reference

SRC homology-2-containing protein tyrosine phosphatase-1 restrains cell proliferation in human medullary thyroid carcinoma.

21 January 2018

1 reference

Role of complex cyclin d1/cdk4 in somatostatin subtype 2 receptor-mediated inhibition of cell proliferation of a medullary thyroid carcinoma cell line in vitro.

21 January 2018

1 reference

Growth-inhibitory effects of human anti-insulin-like growth factor-I receptor antibody (A12) in an orthotopic nude mouse model of anaplastic thyroid carcinoma

21 January 2018

1 reference

Is there a role for sandostatin treatment in patients with progressive thyroid cancer and iodine-negative but somatostatin-receptor-positive metastases?

21 January 2018

1 reference

Expression of somatostatin receptor types 2, 3 and 5 in biopsies and surgical specimens of human lung tumours. Correlation with preoperative octreotide scintigraphy

21 January 2018

1 reference

Expression of somatostatin receptors in uveal melanomas

21 January 2018

1 reference

Distribution and functional significance of somatostatin receptors in malignant melanoma.

21 January 2018

1 reference

Remission of Merkel cell tumor after somatostatin analog treatment

21 January 2018

1 reference

Differential expression of sst1, sst2A, and sst3 somatostatin receptor proteins in low-grade and high-grade astrocytomas

21 January 2018

1 reference

Effect of somatostatin analogue octreotide in medulloblastoma in xenograft and cell culture study

21 January 2018

1 reference

Somatostatin receptors 1, 2, and 5 cooperate in the somatostatin inhibition of C6 glioma cell proliferation in vitro via a phosphotyrosine phosphatase-eta-dependent inhibition of extracellularly regulated kinase-1/2.

21 January 2018

1 reference

Treatment of unresectable skull base meningiomas with somatostatin analogs

21 January 2018

1 reference

Phase II study of subcutaneous octreotide in adults with recurrent or progressive meningioma and meningeal hemangiopericytoma

21 January 2018

1 reference

Treatment of pituitary-dependent Cushing's disease with the multireceptor ligand somatostatin analog pasireotide (SOM230): a multicenter, phase II trial.

21 January 2018

1 reference

Combination of LHRH analog with somatostatin analog and dexamethasone versus chemotherapy in hormone-refractory prostate cancer: a randomized phase II study

21 January 2018

1 reference

Combination of somatostatin analog, dexamethasone, and standard androgen ablation therapy in stage D3 prostate cancer patients with bone metastases

21 January 2018

1 reference

Therapeutic response to somatostatin analogue, BIM 23014, in metastatic prostatic cancer.

21 January 2018

1 reference

A combination therapy of dexamethasone and somatostatin analog reintroduces objective clinical responses to LHRH analog in androgen ablation-refractory prostate cancer patients

21 January 2018

1 reference

Novel concept of antisurvival factor (ASF) therapy produces an objective clinical response in four patients with hormone-refractory prostate cancer: case report.

21 January 2018

1 reference

Combination therapy of ethinylestradiol and somatostatin analogue reintroduces objective clinical responses and decreases chromogranin a in patients with androgen ablation refractory prostate cancer

21 January 2018

1 reference

Feasibility, endocrine and anti-tumour effects of a triple endocrine therapy with tamoxifen, a somatostatin analogue and an antiprolactin in post-menopausal metastatic breast cancer: a randomized study with long-term follow-up

21 January 2018

1 reference

Treatment of patients with metastatic pancreatic and gastrointestinal tumours with the somatostatin analogue Sandostatin: a phase II study including endocrine effects

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.2217/FON.11.66

1 reference

release_afrtsyxbufbbbgpetiysdzj364

25 August 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/afrtsyxbufbbbgpetiysdzj364

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference